Chen, Ying
Tang, Wen-Fang
Lin, Huan
Bao, Hua
Li, Wei
Wang, Ao
Wu, Xue
Su, Jian
Lin, Jie-Shan
Shao, Yang W.
Yang, Xue-Ning
Wu, Yi-Long
Zhong, Wen-Zhao
Funding for this research was provided by:
Health Collaborative Innovation Major Project from Guangzhou Science and Technology Bureau (201400000001-2)
Project of National Natural Science Foundation (81673031, 81872510)
Key Lab System Project of Guangdong Science and Technology Department–Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (2012A061400006/2017B030314120)
Guangdong Provincial People's Hospital Young Talent Project (GDPPHYTP201902)
High-level Hospital Construction Project (DFJH201801)
Article History
Received: 2 June 2019
First Online: 1 April 2020
Disclosure
: Yi-Long Wu received honoraria from AstraZeneca, Eli Lilly, Roche, Pierre Fabre, Pfizer, and Sanofi; served in a consulting or advisory role with AstraZeneca, Roche, Merck, and Boehringer Ingelheim; and had research funding to the institution from Boehringer Ingelheim and Roche. Hua Bao, Ao Wang, Xue Wu and Yang W. Shao worked as employee of Geneseeq Technology Inc for statistical analysis of whole-exome sequencing (WES) in this manuscript. The remaining authors have no conflicts of interest.